SCHEMBL19663688

SCHEMBL19663688

CC(C)(C)C(=O)OCOC(O)c1cccc2c1OB(O)[C@@H](NC(=O)CNC(N)=O)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23129665 0.89 — —
SCHEMBL19663689 0.88 — —
SCHEMBL23129981 0.86 — —
SCHEMBL17337140 0.84 PRKCB (0.34) —
SCHEMBL17337148 0.84 PRKCB (0.34) —
SCHEMBL18797983 0.83 — —
SCHEMBL22667287 0.80 ROCK2 (0.34) —
SCHEMBL23130214 0.79 MTNR1A (0.33) —
SCHEMBL22667282 0.79 — —
SCHEMBL21539650 0.78 MTNR1A (0.35) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9926336-B2 Beta-lactamase inhibitors VENATORX PHARMACEUTICALS (US) 2018-03-27 — — US disclosed
US-20170342092-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-30 — — US disclosed
Send feedback